Stephen K. Burley, Director
Stephen Burley, M.D., D.Phil. is an expert in structural biology, proteomics, bioinformatics, structure/fragment based drug discovery, and clinical medicine/oncology. Burley currently serves as University Professor and Henry Rutgers Chair, Founding Director of the Institute for Quantitative Biomedicine, and Director of the RCSB Protein Data Bank at Rutgers, The State University of New Jersey. He is also a Member of the Rutgers Cancer Institute of New Jersey, where he Co-Leads the Cancer Pharmacology Research Program.
From 2008 to 2012, Burley was a Distinguished Lilly Research Scholar in Lilly Research Laboratories. Prior to joining Lilly, Burley served as the Chief Scientific Officer and Senior Vice President of SGX Pharmaceuticals, Inc., a publicly traded biotechnology company that was acquired by Lilly in 2008. Until 2002, Burley was the Richard M. and Isabel P. Furlaud Professor at The Rockefeller University and an Investigator in the Howard Hughes Medical Institute. He has authored/coauthored more than 260 scholarly scientific articles.
Following undergraduate training in mathematics and physics, Burley received an M.D. degree from Harvard Medical School in the joint Harvard-MIT Health Sciences and Technology Program and, as a Rhodes Scholar, received a D.Phil. in Structural Biology from Oxford University. He trained in internal medicine at the Brigham and Women's Hospital in Boston, and did post-doctoral work with Gregory A. Petsko at the Massachusetts Institute of Technology and William N. Lipscomb, Jr. at Harvard University.
With William J. Rutter and others at the University of California at San Francisco and Rockefeller, Burley co-founded Prospect Genomics, Inc., which was acquired by SGX in 2001.
He is a Fellow of the Royal Society of Canada and of the New York Academy of Sciences, and recipient of a Doctor of Science (Honoris causa) from his alma mater the University of Western Ontario, from which he received a B.Sc. in Physics in 1980.
Publications: Google Scholar